Fagron SA header image

Fagron SA

FAGR

Equity

ISIN BE0003874915 / Valor 3425437

Euronext - Euronext Brussels (2024-11-21)
EUR 18.28+0.55%

Fagron SA
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Fagron SA is a company that operates in a knowledge-intensive niche market, offering customized formulas for pharmacists and prescribers. The company's focus is on informing and training healthcare professionals about compounding through Fagron Academies in the countries where they operate. Fagron aims to improve personalized medicine and make it more accessible for patients, ultimately impacting the health and welfare of people.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (07.08.2024):

Revenue Growth

Fagron SA reported a strong topline performance for the first half of 2024, with a 15.5% increase in reported revenue, reaching €429.3 million. This growth was driven by a 12.8% organic growth at constant exchange rates (CER), reflecting robust performances across all regions.

REBITDA Increase

The company achieved a 17.2% increase in REBITDA, amounting to €84.6 million for the first half of 2024. This improvement translated to a 30 basis points uplift in the REBITDA margin year-on-year, reaching 19.7%, which was attributed to synergies from acquisitions and operational excellence benefits globally.

Net Earnings Per Share

Fagron SA's net earnings per share saw a significant increase of 22.2% year-on-year, reaching €0.55 for the first half of 2024. This growth in earnings per share underscores the company's strong financial performance during the period.

Operating Cash Flow

Operating cash flow for Fagron SA decreased by 3.1% to €41.9 million in the first half of 2024. However, when adjusted for the factoring impact, the operating cash flow actually increased by 34.7%, indicating a strong underlying cash generation capability.

Upgraded Revenue Outlook

Fagron SA has upgraded its full-year 2024 revenue outlook to a range of €850 – €870 million, reiterating an expected improvement in profitability year-on-year. This optimistic outlook is supported by strategic investments and strong underlying demand for the company's services.

Summarized from source with an LLMView Source

Key figures

5.85%1Y
33.0%3Y
3.45%5Y

Performance

17.2%1Y
26.1%3Y
26.9%5Y

Volatility

Market cap

1396 M

Market cap (USD)

Daily traded volume (Shares)

59,292

Daily traded volume (Shares)

1 day high/low

18.34 / 18.02

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Haemonetics Corp
Haemonetics Corp Haemonetics Corp Valor: 937449
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.60%USD 85.43
Evolent Health Inc
Evolent Health Inc Evolent Health Inc Valor: 28153126
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.48%USD 11.59
elf Beauty Inc
elf Beauty Inc elf Beauty Inc Valor: 33775016
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.92%USD 122.47
SOLVENTUM CORP
SOLVENTUM CORP SOLVENTUM CORP Valor: 133635906
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.81%USD 69.63
Inari Medical Inc
Inari Medical Inc Inari Medical Inc Valor: 52764794
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.53%USD 49.75
Progyny Inc
Progyny Inc Progyny Inc Valor: 50342281
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
7.08%USD 14.97
Novo Nordisk A/S
Novo Nordisk A/S Novo Nordisk A/S Valor: 129508879
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.21%DKK 721.80
AbCellera Biologics Inc
AbCellera Biologics Inc AbCellera Biologics Inc Valor: 58489933
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.87%USD 2.72
Conmed Corp
Conmed Corp Conmed Corp Valor: 920278
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.44%USD 71.71
Intuitive Surgical Inc
Intuitive Surgical Inc Intuitive Surgical Inc Valor: 1631646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.62%USD 550.62